Literature DB >> 11536237

Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology.

V Chieux1, W Chehadeh, P Hautecoeur, J Harvey, P Wattré, D Hober.   

Abstract

Interferon alpha (IFN-alpha) is synthesized in response to viral infections. MxA protein, induced specifically by IFN-alpha and beta, expressed in peripheral blood cells, is detected more consistently than circulating IFN-alpha in serum of patients with viral infections. Thus, activation of the IFN-alpha/MxA system can be used as additional marker of the presence of a virus in patients. Therefore MxA protein and IFN-alpha levels were measured in patients with multiple sclerosis (MS), a chronic neurological disease of unknown etiology, in order to investigate the possible role of viruses in the expression of this disease. The means of MxA values obtained by using an immunochemiluminescent assay were significantly higher in blood of patients with remitting (n = 197) or relapsing (n = 39) multiple sclerosis (MS) patients and in patients with viral infections than in blood from healthy controls (n = 25) and from patients with bacterial infections (n = 12). Intra-individual variance in MxA levels in seven clinically stable remitting patients with MS was observed in the course of a follow-up, and high MxA levels were detected in three of them in blood samples collected consecutively over several months. By using an ultra sensitive assay, a higher MxA-inducer activity was obtained with sera from MS patients (n = 39) than with those from healthy controls (n = 12). Experiments with neutralizing antibodies proved that this activity in serum from patients was due to IFN-alpha, whereas IFN-alpha could not be detected by other methods. Altogether these results demonstrate that there is an activation of the IFN-alpha/MxA system in MS patients, which is consistent with the hypothesis that a viral infection may be associated with MS. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536237     DOI: 10.1002/jmv.2034

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Authors:  C Scagnolari; F Bellomi; S Trombetti; M Casato; M Carlesimo; F Bagnato; V Lavolpe; R Bruno; E Millefiorini; L Antonelli; E Girardi; O Turriziani; G Antonelli
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses.

Authors:  Doris Müller-Doblies; Mathias Ackermann; Alfred Metzler
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene.

Authors:  H Schmeisser; J Mejido; C A Balinsky; A N Morrow; C R Clark; T Zhao; K C Zoon
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Authors:  Francesca Gilli; Fabiana Marnetto; Guglielmo Stefanuto; Valentina Rinaldi; Federica Farinazzo; Simona Malucchi; Marco Capobianco; Marzia Caldano; Arianna Sala; Antonio Bertolotto
Journal:  Mol Diagn       Date:  2004

5.  Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.

Authors:  Carolina Scagnolari; Petra Duda; Francesca Bagnato; Gabriella De Vito; Alessia Alberelli; Vito Lavolpe; Enrico Girardi; Valentina Durastanti; Maria Trojano; Ludwig Kappos; Guido Antonelli
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

6.  Association of human myxovirus resistance protein A with severity of COVID-19.

Authors:  Otto Lehtinen; Niklas Broman; Matti Waris; Tytti Vuorinen; Ville Peltola; Eliisa Löyttyniemi; Jarmo Oksi; Thijs Feuth
Journal:  BMC Infect Dis       Date:  2022-09-28       Impact factor: 3.667

Review 7.  Causal inference regarding infectious aetiology of chronic conditions: a systematic review.

Authors:  Sofia Orrskog; Emma Medin; Svetla Tsolova; Jan C Semenza
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

8.  Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic.

Authors:  Michael S Pulia; Terrence P O'Brien; Peter C Hou; Andrew Schuman; Robert Sambursky
Journal:  Ann Med       Date:  2020-05-14       Impact factor: 4.709

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.